Genomic Valley Biotech reports zero Q2 revenue and net loss

Genomic Valley Biotech Limited reported zero revenue in Q2 FY27 and a standalone net loss of ₹0.0198 crore for the quarter ended September 30, 2026, compared with a ₹0.0146 crore profit in the preceding quarter. The result reflects a complete year-on-year and sequential revenue decline in a business operating in the floriculture segment.

What did Genomic Valley Biotech report for Q2 FY27?

Genomic Valley Biotech Limited reported no revenue for the quarter ended September 30, 2026, while recording a standalone net loss of ₹0.0198 crore. The company had reported a profit of ₹0.0146 crore in Q1 FY27. In the corresponding quarter of the previous year, it had recorded a profit of ₹0.0033 crore.

The reported revenue outcome represents a 100% decline both year on year and quarter on quarter, based on the Q2 FY27 result summary. The quarterly result also showed a loss at the operating level. Earnings per share for the quarter stood at negative ₹0.06, according to the disclosed Q2 FY27 data.

The board approved the unaudited standalone financial results for the quarter and half year ended September 30, 2026, at its meeting held on October 30, 2026. The filing included a limited review report from statutory auditor ANDROS & CO. The review report did not provide an audit opinion.

Why did the half-year performance turn negative?

The absence of revenue in the September quarter pushed Genomic Valley Biotech's first-half earnings into a loss. For the six months ended September 30, 2026, total revenue was ₹0.038 crore, down from ₹0.180 crore in H1 FY26.

The company posted a net loss of ₹0.0052 crore in H1 FY27, against a profit of ₹0.0279 crore in the corresponding period a year earlier. The lower revenue base was the central disclosed factor behind the deterioration in the half-year result.

Q1 FY27 had provided the entire reported revenue contribution for the half year. In that quarter, revenue was ₹0.038 crore, net income was ₹0.0146 crore and earnings per share were ₹0.05. The Q1 revenue figure was stated to be 58% lower than the corresponding first quarter of FY26, while net income was 41% lower.

What do the cash-flow and liquidity figures show?

Genomic Valley Biotech ended September 2026 with cash and cash equivalents of ₹0.0004 crore, equivalent to ₹3,626. This was lower than ₹0.0043 crore, or ₹42,936, reported at the end of the previous financial year.

Despite the half-year net loss, the company generated positive operating cash flow of ₹0.0193 crore during H1 FY27. The disclosure attributed this positive cash flow primarily to a reduction in trade receivables and an increase in current liabilities rather than to operating profitability.

This distinction is important when assessing the period's cash generation. A reduction in amounts receivable from customers can release cash, while higher current liabilities can preserve cash temporarily. Neither item changes the reported absence of Q2 revenue or the loss recorded for the quarter.

How does the result compare with the company's recent reporting history?

Genomic Valley Biotech's Q2 FY27 outcome followed a profitable first quarter but came after revenue had already contracted sharply in Q1 FY27. The company had reported first-quarter revenue of ₹0.038 crore and a profit margin of 39%, compared with 27% in Q1 FY26. The stated improvement in that margin was linked to lower expenses.

The September-quarter result reversed that quarterly profit because no revenue was reported. The supplied quarterly figures show revenue rounded to zero across several recent quarters, which also highlights the small absolute scale of the company's reported operations and results.

For longer-term context, the company's director's report for FY25 recorded profit after tax of ₹0.3561 crore, compared with ₹0.0152 crore in the prior year, with FY25 earnings per share of ₹1.17. Those annual figures predate the current half-year period and should not be treated as a guide to the Q2 FY27 operating outcome.

What does the Q2 FY27 result mean for investors?

The Q2 FY27 result shows that Genomic Valley Biotech entered the second half of FY27 after a quarter with no reported revenue, a net loss and a materially lower cash balance. For investors, the key reported measures are the revenue decline from ₹0.180 crore to ₹0.038 crore in the first half and the shift from an H1 profit to a loss.

The positive operating cash flow provides some context but does not indicate that the business generated cash from profitable operations during the period. The company specifically linked the cash inflow to working-capital changes, including lower receivables and higher current liabilities.

The October 30 board approval was a required reporting step and the supplied filing did not disclose performance targets or future financial guidance. As a result, the available information establishes the financial position through September 30, 2026, without confirming a timeline for revenue recovery.

Conclusion

Genomic Valley Biotech's Q2 FY27 results showed zero revenue and a ₹0.0198 crore net loss, turning its H1 FY27 performance into a loss despite a profitable first quarter. Revenue for the first half fell to ₹0.038 crore from ₹0.180 crore a year earlier, while cash and cash equivalents declined to ₹0.0004 crore.

The next area to watch is the company's subsequent quarterly disclosure for evidence of revenue generation after the zero-revenue September quarter. Investors can also monitor changes in cash, receivables and current liabilities, given that positive H1 operating cash flow was driven by working-capital movements rather than operating profitability.